ROCKVILLE, Md., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the treatment of cancer, today announced it will present the preliminary Phase Ib/IIa efficacy data for RX-3117 in metastatic pancreatic cancer and an update on the Supinoxin™ Phase I clinical trial at the 2016 European Society for Medical Oncology (ESMO) Congress, which will take place October 7 th – 11 th in Copenhagen, Denmark.
Poster sessions:
RX-3117, an oral antimetabolite to treat advanced solid tumors (ST): Phase 1 and ongoing phase 2a results. D. Rasco (San Antonio, United States of America), C. Peterson (Rockville, United States of America), R. Mazhari (Rockville, United States of America), E. Benaim (Rockville, United States of America), and J. Merchan (Miami, United States of America) (Abstract 396P)
Date/time: Monday October 10, 2016, 13:00 – 14:00 (CEST)
Location: Hall E
Phase 1/2a study of RX-5902 in advanced solid tumors (ST): An orally bioavailable inhibitor of phosphorylated P68 and modulator of β-catenin nuclear translocation. S. Eckhardt (Denver, United States of America) , W. L. Gluck (Greenville, United States of America), M. Gutierrez (Hackensack, United States of America), C. Peterson (Rockville, United States of America), R. Mazhari (Rockville, United States of America), and E. Benaim (Rockville, United States of America) (Abstract 385P)
Date/time: Monday October 10, 2016, 13:00 – 14:00 (CEST)
Location: Hall E
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer. The Company's mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Pre-clinical studies show that certain of Rexahn's product candidates may be effective against multiple types of cancer, drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: Supinoxin™, RX-3117, and Archexin ® , and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information about the Company and its oncology programs, please visit www.rexahn.com .
Safe Harbor
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn's plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, enrollments in clinical trials, the path of clinical trials and development activities, and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn's actual results to be materially different than those expressed in or implied by Rexahn's forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, understandings and beliefs regarding the role of certain biological mechanisms and processes in cancer; drug candidates being in early stages of development, including in pre-clinical development; the ability to initially develop drug candidates for orphan indications to reduce the time-to-market and take advantage of certain incentives provided by the U.S. Food and Drug Administration; and the ability to transition from our initial focus on developing drug candidates for orphan indications to candidates for more highly prevalent indications. More detailed information on these and additional factors that could affect Rexahn's actual results are described in Rexahn's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
LifeSci Advisors, LLC Matthew P. Duffy (212)-915-0685 matthew@lifesciadvisors.com
